The FDA approves first drug to treat tardive dyskinesia; Americans use crowdfund sites to pay for prescriptions; stroke sufferers struggle with adherence
A high-profile cancer track commands attention, while wearables and IBM Watson Health come under fire.
Researchers question relationship between R&D costs and drug prices; Alexa uses WebMD to answer health questions; lawmakers push GAO to investigate orphan drugs
Really? Is this the new healthcare math — the fewer the insurance companies, the greater the competition and the lower the premiums?
Type 2 diabetes is on the rise, around the world. The IMS Institute for Healthcare Informatics breaks down diabetes prevalence in Brazil, Mexico, Saudi Arabia, the U.K., and the U.S.
- Five things for pharma marketers to know: Monday, April 24, 2017
- Five things for pharma marketers to know: Thursday, April 20, 2017
- Five things for pharma marketers to know: Friday, April 21, 2017
- Five things for pharma marketers to know: Tuesday, April 25, 2017
- Five things for pharma marketers to know: Wednesday, April 26, 2017
- How pharma marketers are using behavioral science
- Veeva and QuintilesIMS tussle over customer reference data
- Genentech urges broader adoption of value-based payment models
- Some brands thought to shift online ad dollars, creating uncertainty for WebMD
- Study: Medical-marijuana laws lower prescription drug usage